Biogen (BIIB) PT Raised to $300 at Wedbush, After FDA Approves Aduhelm (Aducanumab)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $252.29 +3.38%
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 23 | New: 16
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 23 | New: 16
Join SI Premium – FREE
Wedbush analyst Laura Chico raised the price target on Biogen (NASDAQ: BIIB) to $300.00 (from $240.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $275 at Freedom Broker
- TAL International (TAL) PT Lowered to $11.50 at Jefferies
- Biogen (BIIB) PT Raised to $238 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
